(MT Newswires covers equity, commodity and economic research from major banks and research firms in North America, Asia and Europe. Research providers may...
(MT Newswires covers equity, commodity and economic research from major banks and research firms in North America, Asia and Europe. Research providers may...
...
BioXcel Therapeutics (BTAI) said Tuesday that it has created a wholly owned subsidiary called OnkosXcel Therapeutics, Inc. to develop transformative...
| Address | 555 Long Wharf Drive New Haven, Connecticut 06511 |
| Phone | +1.475.238.6837 |
| Number of Employees | 18 |
| Recent SEC Filing | 05/09/2022 8-K |
| President, Chief Executive Officer & Director | Vimal D. Mehta |
| Chief Financial Officer & Vice President | Richard I. Steinhart |
| Chief Scientific Officer & Senior Vice President | Frank D. Yocca |
| Chief Medical Officer & Senior Vice President | Vincent J. O'Neill |
| Price Open | $12.32 |
| Previous Close | $12.03 |
| 52 Week Range | $9.08 - 39.00 |
| Market Capitalization | $381.2 M |
| Shares Outstanding | 28.0 M |
| Sector | Health Technology |
| Industry | Biotechnology | Next Earnings Announcement | 08/09/2022 |
| Call Open Interest (1d)* |  |
| Put Open Interest (1d)* | |
| Call Volume (1d)* | |
| Put Volume (1d)* | |
| Put Call Open Interest Ratio (1d)* | |
| Put Call Volume Ratio (1d)* | |
| * Data delayed by up to 15 minutes |
| Price / Earnings | N/A |
| Earnings per Share | -$4.10 |
| Beta vs. S&P 500 | N/A |
| Revenue | $0.00 |
| Net Profit Margin | N/A |
| Return on Equity | -48.25% |
| Buy | |
| Overweight | |
| Hold | |
| Underweight | |
| Sell | |
Consensus Recommendation | |
